SEHK:1177Pharmaceuticals
Assessing Sino Biopharmaceutical (SEHK:1177) Valuation After Fresh IPF And Psoriasis Trial Milestones
Sino Biopharmaceutical (SEHK:1177) has just reported two key clinical milestones, including first patient enrollment in a Phase III trial for IPF drug candidate TDI01 and positive Phase II data for psoriasis treatment TQH3906.
See our latest analysis for Sino Biopharmaceutical.
The latest clinical updates arrive after a mixed year for Sino Biopharmaceutical’s shares. The stock has a 7.39% year-to-date share price return at HK$6.83, a 12.44% decline over 90 days, and a very large 1-year total...